SCHEMBL25294091

SCHEMBL25294091

Cc1cn(-c2ccccc2)c(C=O)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
ATM Q13315 2/20 0.43
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 2/20 0.42
CYP1A2 P05177 1/20 0.42
HPGD P15428 1/20 0.42
BLM P54132 1/20 0.42
HSD17B10 Q99714 1/20 0.42
P2RX7 Q99572 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
TSHR P16473 1/20 0.36
NOTUM Q6P988 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
COMT P21964 1/20 0.35
GAA P10253 1/20 0.35
SCN2B O60939 1/20 0.33
SCN1A P35498 1/20 0.33
SCN1B Q07699 1/20 0.33
SCN5A Q14524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26304764 0.80 KDM4E (0.37) SMN1; SMN2ATMALDH1A1KDM4ECYP1A2
SCHEMBL5858717 0.74 ALDH1A1 (0.50) SMN1; SMN2ATMALDH1A1KDM4ECYP1A2
SCHEMBL11350307 0.74 KDM4E (0.44) SMN1; SMN2ALDH1A1KDM4ECYP1A2HPGD
SCHEMBL27889164 0.73 ALDH1A1 (0.40) SMN1; SMN2ATMALDH1A1KDM4ECYP1A2
SCHEMBL25241188 0.71 TTR (0.53) HPGDGAAPTGS2
SCHEMBL25287575 0.71 TTR (0.53) HPGDGAAPTGS2
SCHEMBL28852170 0.70 ATM (0.43) SMN1; SMN2ATMALDH1A1KDM4ECYP1A2
SCHEMBL14827205 0.70 ATM (0.47) SMN1; SMN2ATMALDH1A1KDM4ECYP1A2
SCHEMBL12137618 0.67 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1KDM4ECYP1A2HPGD
SCHEMBL13817620 0.67 ATM (0.52) SMN1; SMN2ATMALDH1A1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME MEDIFIC, INC. (KR) 2025-02-27 US disclosed
EP-4455143-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME Medific, Inc. (KR) 2024-10-30 EP disclosed
CN-118591539-A Substituted thiazolidinedione derivative compounds and pharmaceutical composition for preventing or treating cancer comprising the same (株)美迪菲 2024-09-03 CN disclosed
WO-2023121184-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME (주)메디픽 2023-06-29 WO disclosed
WO-2023121184-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME (주)메디픽 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME SREBF1, SREBF2, SP1 SMN1; SMN2 4042/4885ATM 914/4885ALDH1A1 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.